A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

This study is testing an intensive treatment approach for primary plasma cell leukaemia — a rare and aggressive blood cancer — combining targeted drug therapy (VRD: bortezomib, lenalidomide, dexamethasone) with two rounds of CAR-T cell therapy and a stem cell transplant in between. **You may be eligible if...** - You are between 18 and 65 years old - You have been newly diagnosed with primary plasma cell leukaemia (confirmed by specific diagnostic criteria) - Your performance status is good (ECOG 0–2) - Your heart, liver, kidney, and lung function meet the required levels **You may NOT be eligible if...** - You are over 65 years old - You have previously received treatment for this condition - You have significant organ dysfunction or another active cancer - You have active, uncontrolled infection Talk to your doctor to see if this trial is right for you.